Table 3

IFN-DCs	CD3^⁺IFN-γ⁺ Т-cells (%)			CD3⁺IL-4⁺Т-cells (%)
IFN-DCs	0	+DC	SI	0	+DC	SI
Healthy donors (n=20)	1.9 ± 0.3	6.1 ± 0.5	4.8 ± 0.9	1.8 ± 0.1	2.2 ± 0.3	1.3 ± 0.2
TB patients (n=36)	1.9 ± 0.1	3.1 ± 0.4 ^*	1.8 ± 0.2^*	2.0 ± 0.2	4.7 ± 0.6^*	2.2 ± 0.2 ^*
PPD-responsive patients (n=17)	1.7 ± 0.1	3.7 ± 0.6	2.4 ± 0.3^*	1.8 ± 0.2	2.8 ± 0.4	1.6 ± 0.1
PPD- anergic patients (n=19)	2.1 ± 0.1	2.7 ± 0.5^*#	1.3 ± 0.2^*#	2.4 ± 0.3	6.7 ± 1.1^*#	2.8 ± 0.3^*#

Note: The percentage of CD3⁺T-cells with intracellular expression of IFN-γ (CD3⁺IFN-γ⁺Т-cells) and IL-4 (CD3⁺IL-4⁺Т-cells) was assessed in the cultures of donor PBMCs, depleted from monocytes (0), and activated with allogeneic DCs (⁺DC) during 5 days and than re-stimulated with the same DCs for additional 48 h. SI: Stimulation Index of DCs; ^*-p_U<0.05 vs healthy donors; ^#-p_U<0.05 vs PPDreactive patients

Table 3: The capacity of cultured IFN-DCs to stimulate CD3⁺IFN-γ⁺ and CD3⁺IL-4⁺ Т-cells in MLC.